Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Viewpoint - Genmab has made significant progress in its late-stage programs, particularly with three key assets that have received FDA breakthrough therapy designations, indicating strong potential for future growth and product launches [2]. Group 1: Company Progress - Genmab's late-stage programs include EPKINLEY, Rina-S, and peto, all of which have received at least one FDA breakthrough therapy designation [2]. - The company has observed significant clinical data developments in 2025 that have bolstered confidence in these programs [2]. - Looking ahead to 2026, Genmab anticipates meaningful registrational data that could lead to important product launches in 2027 [2].